Pulmonary arterial hypertension associated with systemic sclerosis

Area of Science:

• Cardiology
• Rheumatology
• Pulmonology

Background:

• Systemic sclerosis (SSc) frequently leads to pulmonary arterial hypertension (PAH), a primary cause of death.
• Screening for PAH in SSc patients is crucial due to the high incidence, yet optimal methods are undefined.
• Existing PAH therapies demonstrate limited effectiveness in SSc-PAH patients.

Purpose of the Study:

• To review the challenges and potential new therapeutic avenues for pulmonary arterial hypertension in systemic sclerosis.
• To highlight the limitations of current outcome measures and the heterogeneity of SSc-PAH.
• To discuss the relevance of novel therapies targeting pulmonary vascular proliferation in SSc-PAH.

Main Methods:

• Literature review of current research on SSc-PAH.
• Analysis of treatment responses and outcome measures in SSc-PAH.
• Discussion of emerging therapeutic strategies for pulmonary vascular disease.

Main Results:

• Recent PAH therapies have shown discouraging responses in SSc-PAH patients.
• Current outcome measures may not adequately capture treatment effects in SSc-PAH.
• Disease heterogeneity within SSc contributes to variable responses to PAH treatments.

Conclusions:

• Novel therapies targeting abnormal cellular proliferation in pulmonary vasculature are under investigation for SSc-PAH.
• Extrapulmonary organ involvement in SSc restricts lung transplant eligibility, increasing the need for effective medical therapies.
• Further research is needed to define optimal screening modalities and develop effective treatments for SSc-PAH.